Results 21 to 30 of about 1,274,904 (321)

Characteristics of SARS-CoV-2 and COVID-19

open access: yesNature Reviews Microbiology, 2020
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus that emerged in late 2019 and has caused a pandemic of acute respiratory disease, named ‘coronavirus disease 2019’ (COVID-19), which ...
Ben Hu, Hua Guo, P. Zhou, Zhènglì Shí
semanticscholar   +1 more source

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

open access: yesScience, 2021
UK variant transmission Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has the capacity to generate variants with major genomic changes. The UK variant B.1.1.7 (also known as VOC 202012/01) has many mutations that alter virus attachment and
N. Davies   +22 more
semanticscholar   +1 more source

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

open access: yesNew England Journal of Medicine, 2020
SARS-CoV-2 Viral Load in Upper Respiratory Specimens The authors report results of an analysis of nasal and throat swabs from 17 patients in Zhuhai, China, who had received a diagnosis of Covid-19....
L. Zou   +15 more
semanticscholar   +1 more source

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

open access: yesScience, 2021
Variable memory Immune memory against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) helps to determine protection against reinfection, disease risk, and vaccine efficacy.
J. Dan   +20 more
semanticscholar   +1 more source

Diagnosis and Management of COVID-19 Disease [PDF]

open access: yes, 2020
SARS-CoV-2 is a novel coronavirus that was identified in late 2019 as the causative agent of COVID-19 (aka coronavirus disease 2019). On March 11, 2020, the World Health Organization (WHO) declared the world-wide outbreak of COVID-19 a pandemic.
Carlos, Graham   +5 more
core   +1 more source

A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing

open access: yesNature, 2020
A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals
D. Gordon   +124 more
semanticscholar   +1 more source

Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples

open access: yesScientific Reports, 2022
Loop-mediated isothermal amplification is known for its high sensitivity, specificity and tolerance to inhibiting-substances. In this work, we developed a device for performing real-time colorimetric LAMP combining the accuracy of lab-based quantitative ...
G. Papadakis   +17 more
doaj   +1 more source

Acute parkinsonism secondary to SARS Cov 2 infection. [PDF]

open access: yesBatna Journal of Medical Sciences, 2023
SARS Cov 2 or Corona virus is a respiratory virus, responsible for a new pandemic since 2019. Main symptoms revolve around respiratory manifestations. Nevertheless, many extra-respiratory attacks are attributed to it.
Mohamed Islam Kediha   +3 more
doaj   +1 more source

Mechanisms of SARS-CoV-2 entry into cells

open access: yesNature reviews. Molecular cell biology, 2021
The unprecedented public health and economic impact of the COVID-19 pandemic caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been met with an equally unprecedented scientific response.
C. B. Jackson   +3 more
semanticscholar   +1 more source

Commercial stocks of SARS-CoV-2 RNA may report low concentration values, leading to artificially increased apparent sensitivity of diagnostic assays [PDF]

open access: yes, 2020
In response to the rapidly evolving COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) has rapidly issued 49 emergency use authorizations (EUAs) for SARS-CoV-2 in vitro diagnostic test-kits. A critical metric in the performance evaluation for
Ismagilov, Rustem F., Jue, Erik
core   +1 more source

Home - About - Disclaimer - Privacy